ZA8:FRA
Zymeworks Inc
€21.92
arrow_upward
+0.78%(+0.17) 1D
Oct 20, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZA8...
Open
€22.42
High
€22.42
Low
€21.92
Mkt. cap
1.91B
Avg. vol.
0.00
Volume
0.00
52-wk high
€26.33
52-wk low
€13.70
No. of employees
231
Open
€22.42
High
€22.42
Low
€21.92
Mkt. cap
1.91B
Avg. vol.
0.00
Volume
0.00
52-wk high
€26.33
52-wk low
€13.70
No. of employees
231
News stories
From web sources and news partners
ad-hoc-news.de
·
13 hours ago
Zymeworks appoints Suzanne Monahan. Truist sets USD 34 target for Zymeworks stock
Investing.com
·
1 day ago
Zymeworks appoints Suzanne Monahan as commercial head
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees231
Founded2003
HeadquartersVancouver, British Columbia, Canada
SectorBiotechnology
Websitezymeworks.com